After working at two pharma CVCs, Hamzeh Abdul Hadi has joined Angelini Ventures as a health tech investor in Dubai.
Hamzeh Abdul Hadi has joined Italian industrial group Angelini’s VC arm, Angelini Ventures, as senior principal.
Based in Dubai, he will look at health tech investments for the investment unit. He was investment director at pharmaceutical company Debiopharm’s VC arm, Debiopharm Innovation Fund. He was also at Hikma Ventures, the VC arm of pharmaceutical firm Hikma, for nearly six years.
He also founded Al-Alpha Health, a men’s sexual health platform provider.
Angelini is a large, privately owned, diversified group, with business lines in health, consumer goods and industrial technology.
Its CVC, Angelini Ventures, which recently struck a deal with the European Investment Bank to back 10 European health tech startups from a €150m ($177m) fund, recently invested in targeted therapy company Laigo Bio, neurological activity monitoring system developer CoMind and antibody-based cancer treatment developer Adcytherix.
See Angelini Ventures’ recent funding rounds in the CVC Funding Round Database
Fernando Moncada Rivera
Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
